FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis
[unable to retrieve full-text content]INCHEON, Korea and CAMBRIDGE, Mass. – September 20, 2021 – Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), a biosimilar… Drugs.com – New Drug Approvals